Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADMANASDAQ:CALTNASDAQ:CYTKNASDAQ:KRYS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMAADMA Biologics$24.51+12.1%$18.97$6.49▼$25.67$5.82B0.533.67 million shs10.25 million shsCALTCalliditas Therapeutics AB (publ)$40.00$40.00$15.25▼$43.00$1.19B1.7710,339 shsN/ACYTKCytokinetics$41.22+2.0%$41.99$32.74▼$68.44$4.91B0.941.61 million shs846,787 shsKRYSKrystal Biotech$169.73+1.0%$176.24$141.72▼$219.34$4.90B0.75295,598 shs167,657 shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMAADMA Biologics0.00%+2.58%+7.90%+35.02%+233.74%CALTCalliditas Therapeutics AB (publ)0.00%0.00%0.00%0.00%+105.12%CYTKCytokinetics0.00%+2.41%-6.39%-19.04%-38.12%KRYSKrystal Biotech0.00%-0.30%-8.62%+5.66%+7.13%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADMAADMA Biologics1.5114 of 5 stars1.61.00.00.03.61.71.9CALTCalliditas Therapeutics AB (publ)N/AN/AN/AN/AN/AN/AN/AN/ACYTKCytokinetics4.134 of 5 stars4.52.00.04.62.70.80.0KRYSKrystal Biotech4.9073 of 5 stars4.53.00.04.73.03.31.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADMAADMA Biologics 3.25Buy$22.50-8.20% DownsideCALTCalliditas Therapeutics AB (publ) 2.00Hold$39.25-1.88% DownsideCYTKCytokinetics 2.94Moderate Buy$79.1391.96% UpsideKRYSKrystal Biotech 3.00Buy$222.7131.22% UpsideCurrent Analyst Ratings BreakdownLatest CALT, KRYS, ADMA, and CYTK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/28/2025KRYSKrystal BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$221.00 ➝ $240.004/24/2025CYTKCytokineticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight ➝ Overweight$55.004/21/2025CYTKCytokineticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$120.00 ➝ $120.004/15/2025CYTKCytokineticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$62.00 ➝ $54.004/15/2025CYTKCytokineticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$120.00 ➝ $120.004/10/2025CYTKCytokineticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$78.00 ➝ $78.004/8/2025CYTKCytokineticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$72.00 ➝ $72.004/4/2025CYTKCytokineticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$120.00 ➝ $120.003/7/2025CYTKCytokineticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$67.003/5/2025KRYSKrystal BiotechJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$245.003/4/2025ADMAADMA BiologicsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$25.00 ➝ $25.00(Data available from 4/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADMAADMA Biologics$426.45M13.66$0.08 per share311.70$0.60 per share40.85CALTCalliditas Therapeutics AB (publ)$1.60B0.74N/AN/A$1.06 per share37.74CYTKCytokinetics$18.47M265.94N/AN/A($3.94) per share-10.46KRYSKrystal Biotech$290.52M16.88$4.31 per share39.38$32.85 per share5.17Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADMAADMA Biologics-$28.24M$0.8287.5435.52N/A17.80%53.20%26.07%5/8/2025 (Estimated)CALTCalliditas Therapeutics AB (publ)-$43.96M-$1.85N/A8.68N/A-30.18%-212.04%-27.96%N/ACYTKCytokinetics-$526.24M-$5.26N/AN/AN/A-17,906.25%N/A-50.21%5/6/2025 (Estimated)KRYSKrystal Biotech$10.93M$2.9956.7716.84N/A30.69%11.41%10.40%5/6/2025 (Estimated)Latest CALT, KRYS, ADMA, and CYTK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025ADMAADMA Biologics$0.16N/AN/AN/A$116.40 millionN/A5/6/2025Q1 2025CYTKCytokinetics-$1.41N/AN/AN/A$2.77 millionN/A5/6/2025Q1 2025KRYSKrystal Biotech$1.35N/AN/AN/A$98.66 millionN/A2/27/2025Q4 2024CYTKCytokinetics-$1.29-$1.26+$0.03-$1.26$14.26 million$16.93 million2/24/2025Q4 2024KRYSKrystal Biotech$1.29$1.52+$0.23$1.52$91.35 million$91.10 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADMAADMA BiologicsN/AN/AN/AN/AN/ACALTCalliditas Therapeutics AB (publ)N/AN/AN/AN/AN/ACYTKCytokineticsN/AN/AN/AN/AN/AKRYSKrystal BiotechN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADMAADMA Biologics0.487.093.26CALTCalliditas Therapeutics AB (publ)9.442.692.59CYTKCytokinetics5.939.289.28KRYSKrystal BiotechN/A7.287.76Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADMAADMA Biologics75.68%CALTCalliditas Therapeutics AB (publ)2.83%CYTKCytokineticsN/AKRYSKrystal Biotech86.29%Insider OwnershipCompanyInsider OwnershipADMAADMA Biologics3.70%CALTCalliditas Therapeutics AB (publ)2.20%CYTKCytokinetics3.40%KRYSKrystal Biotech13.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADMAADMA Biologics530237.62 million227.64 millionOptionableCALTCalliditas Therapeutics AB (publ)18029.79 million29.14 millionOptionableCYTKCytokinetics250119.19 million114.00 millionOptionableKRYSKrystal Biotech21028.90 million24.71 millionOptionableCALT, KRYS, ADMA, and CYTK HeadlinesRecent News About These CompaniesKrystal Biotech, Inc. (NASDAQ:KRYS) Shares Purchased by Decheng Capital LLCApril 28 at 7:18 AM | marketbeat.comKrystal Biotech Announces European Commission Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis BullosaApril 28 at 7:00 AM | globenewswire.comLord Abbett & CO. LLC Sells 68,531 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)April 28 at 6:09 AM | marketbeat.comKrystal Biotech, Inc. (NASDAQ:KRYS) Shares Acquired by LPL Financial LLCApril 28 at 3:06 AM | marketbeat.comTower Research Capital LLC TRC Raises Position in Krystal Biotech, Inc. (NASDAQ:KRYS)April 27 at 5:00 AM | marketbeat.comWells Fargo & Company MN Boosts Stock Holdings in Krystal Biotech, Inc. (NASDAQ:KRYS)April 27 at 3:15 AM | marketbeat.comXTX Topco Ltd Acquires Shares of 2,102 Krystal Biotech, Inc. (NASDAQ:KRYS)April 26 at 4:15 AM | marketbeat.comBarclays PLC Sells 4,111 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)April 26 at 4:06 AM | marketbeat.comKrystal Biotech, Inc. (NASDAQ:KRYS) Shares Bought by Hood River Capital Management LLCApril 25 at 7:19 AM | marketbeat.comTD Cowen Sticks to Its Buy Rating for Krystal Biotech (KRYS)April 24, 2025 | markets.businessinsider.comPittsburgh biotech firms benefit in potential pharma tariffs and domestic manufacturing shiftApril 24, 2025 | bizjournals.comKrystal Biotech to Present at Upcoming Scientific ConferencesApril 24, 2025 | globenewswire.comIBD Rating Upgrades: Krystal Biotech Flashes Improved Relative Price StrengthApril 23, 2025 | msn.comKrystal Biotech, Inc. (NASDAQ:KRYS) is Avoro Capital Advisors LLC's 5th Largest PositionApril 23, 2025 | marketbeat.com102,061 Shares in Krystal Biotech, Inc. (NASDAQ:KRYS) Purchased by Raymond James Financial Inc.April 23, 2025 | marketbeat.comS Squared Technology LLC Acquires 20,000 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)April 19, 2025 | marketbeat.comKrystal Biotech, Inc. (NASDAQ:KRYS) Position Reduced by Invesco Ltd.April 19, 2025 | marketbeat.comBank of America Securities Sticks to Their Buy Rating for Krystal Biotech (KRYS)April 18, 2025 | markets.businessinsider.comFate Therapeutics' Lupus Candidate FT819 Gets FDA RMAT TagApril 15, 2025 | msn.comKennedy Capital Management LLC Grows Position in Krystal Biotech, Inc. (NASDAQ:KRYS)April 15, 2025 | marketbeat.comAbeona Therapeutics: An Uncertain Pivotal Regulatory Catalyst With Limited Long-Term UpsideApril 14, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAre Tariffs Threatening Disney’s Comeback Story?By Jea Yu | April 9, 2025View Are Tariffs Threatening Disney’s Comeback Story?Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Signs of a more buyer-friendly housing market emerge for the spring homebuying seasonBy The Associated Press | April 6, 2025View Signs of a more buyer-friendly housing market emerge for the spring homebuying season5 Highest-Rated Dividend Stocks According to MarketBeatBy Thomas Hughes | April 10, 2025View 5 Highest-Rated Dividend Stocks According to MarketBeatIntel’s Big Bet on 18A: Will Lip-Bu Tan’s Vision Pay Off?By Jeffrey Neal Johnson | April 4, 2025View Intel’s Big Bet on 18A: Will Lip-Bu Tan’s Vision Pay Off?CALT, KRYS, ADMA, and CYTK Company DescriptionsADMA Biologics NASDAQ:ADMA$24.51 +2.65 (+12.12%) Closing price 04:00 PM EasternExtended Trading$24.60 +0.09 (+0.39%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.Calliditas Therapeutics AB (publ) NASDAQ:CALT$40.00 0.00 (0.00%) As of 04/25/2025Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden.Cytokinetics NASDAQ:CYTK$41.22 +0.79 (+1.95%) Closing price 04:00 PM EasternExtended Trading$40.52 -0.70 (-1.69%) As of 04:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.Krystal Biotech NASDAQ:KRYS$169.73 +1.67 (+0.99%) Closing price 04:00 PM EasternExtended Trading$169.74 +0.01 (+0.01%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet Rebounds After Strong Earnings and Buyback Announcement Could Selling Taiwan Semiconductor Be Buffett’s Biggest Regret? The Bear Market Has Only Just Started - Here's Why MarketBeat Week in Review – 04/21 - 04/25 3 Top Big Pharma Stocks Investing Over $100 Billion in the U.S. PepsiCo’s Stock Price is Disconnected From Reality: Time to Buy Bears Can Reap Big Benefits With These 3 Short ETF Bets Why Institutions Are Buying Super Micro Computer Stock Again Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
